Biosimilar Bevacizumab Market Research Report Information By Product (Avastin, Mvasi, Zirabev, Aybintio, and Other Clinical Trial Products), By Application (Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, and Ovarian Cancer) By Distribution Channels (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Other Direct Distribution Channels) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Biosimilar Bevacizumab Market Overview

The Biosimilar Bevacizumab Market size was valued at USD 1.4 Billion in 2022. The biosimilar bevacizumab industry is projected to grow from USD 1.52 Billion in 2023 to USD 3.04 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.0% during the forecast period (2024 - 2032). Rising expenditure for research & development proficiencies, increasing prevalence of cancer, and increasing healthcare expenditure are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Biosimilar Bevacizumab Market Trends

• 
  

  Advancing product innovation is driving market growth

  
  

Market CAGR for biosimilar bevacizumab is being driven by the advancing product innovation. Advancing product innovation in the biosimilar bevacizumab market entails leveraging cutting-edge technologies and research methodologies to develop high-quality alternatives to the original drug. This involves refining manufacturing processes, enhancing therapeutic efficacy, and ensuring regulatory compliance. By driving innovation, companies can expand market access, improve patient outcomes, and foster competition, ultimately leading to increased affordability and accessibility of this critical biologic therapy.

Additionally, key players in the market employ diverse strategies for market dominance. These include aggressive pricing to compete with originator products, strategic partnerships for distribution channels, and robust R&D investments to enhance product efficacy. Some focus on regulatory compliance for swift market entry, while others prioritize extensive clinical trials for product differentiation. Overall, these strategies aim to capitalize on the growing demand for affordable and quality biosimilar alternatives in the bevacizumab market.

For instance, in February 2024, Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd, announced a five-year partnership with Sandoz AG ('Sandoz'), which provides Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia, thus driving the biosimilar bevacizumab market revenue.

Biosimilar Bevacizumab Market Segment Insights

Biosimilar Bevacizumab Product Insights

The Biosimilar Bevacizumab Market segmentation, based on product, includes avastin, mvasi, zirabev, aybintio, and other clinical trial products. In 2023, the avastin segment dominated the market, accounting for 35% of market revenue. The category growth is driven by the increasing prevalence of cancer, rising demand for affordable treatment options, and patent expirations of branded drugs. Regulatory approvals for biosimilars, coupled with initiatives promoting their adoption, further stimulate market growth. These dynamics reshape the landscape, fostering accessibility and affordability of life-saving therapies for patients worldwide.

Biosimilar Bevacizumab Application Insights

The Biosimilar Bevacizumab Market segmentation, based on application, includes colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. In 2023, the ovarian cancer category generated the most income. The rising prevalence of colorectal cancer and the demand for more affordable treatment options fuel market growth. Additionally, patent expirations of reference biologics pave the way for biosimilar entry, fostering competition and driving down prices. Moreover, favorable regulatory pathways for biosimilar approval encourage market expansion. Overall, increasing accessibility to cost-effective therapies for colorectal cancer patients propels the market forward.

Biosimilar Bevacizumab Distribution Channels Insights

The Biosimilar Bevacizumab Market segmentation, based on distribution channels, includes hospital pharmacy, online pharmacy, retail pharmacy, and other direct distribution channels. In 2023, the hospital pharmacy category generated the most income. Cost-effectiveness and accessibility are significant drivers in the market, compelling hospitals to integrate these alternatives into their formularies. With increasing pressure to contain healthcare costs without compromising patient care, hospitals seek biosimilars as viable alternatives to expensive originator biologics, enhancing affordability and patient access to critical treatments.

Figure 1: Biosimilar Bevacizumab Market, by Biomarker Type, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Biosimilar Bevacizumab Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American biosimilar bevacizumab market area will dominate this market, owing to the increasing demand for cost-effective cancer treatments that propel the adoption of biosimilars. Efforts to address healthcare affordability concerns and the potential for biosimilars to reduce healthcare expenditure stimulate market demand in North America. Further, the US market held the largest market share, and the Canadian biosimilar bevacizumab market was the fastest-growing market in the North American region.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 2: Biosimilar Bevacizumab Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe biosimilar bevacizumab market accounts for the second-largest market share due to regulatory approvals for biosimilar drugs, cost-effectiveness compared to reference biologics, and the increasing prevalence of cancer. Further, the German biosimilar bevacizumab market held the largest market share, and the UK biosimilar bevacizumab market was the fastest-growing market in the European region.

The Asia-Pacific biosimilar bevacizumab market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to supportive government initiatives to promote their adoption, growing investments in healthcare infrastructure, advancements in biotechnology & favorable reimbursement policies, and expanding research collaborations. Moreover, China’s biosimilar bevacizumab market held the largest market share, and the Indian biosimilar bevacizumab market was the fastest-growing market in the Asia-Pacific region.

Biosimilar Bevacizumab Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the biosimilar bevacizumab market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the biosimilar bevacizumab industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global biosimilar bevacizumab industry to benefit clients and increase the market sector. In recent years, the biosimilar bevacizumab industry has offered some of the most significant advantages to medicine. Major players in the biosimilar bevacizumab market, including Amgen, AryoGen Pharmed, Biothera, Boehringer Ingelheim, Centus Biotherapeutics, Henlius Biotech, and others, are attempting to increase market demand by investing in research and development operations.

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders, and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has a presence in Asia Pacific, Europe, the Middle East, North America, and Australia. Amgen is headquartered in Thousand Oaks, California, the US. In July 2019, Amgen and Allergan announced the launch of Mvasi, a bevacizumab biosimilar referencing Avastin, and Kanjinti, a trastuzumab biosimilar referencing Herceptin, in the United States.

Amneal Pharmaceuticals Inc (Amneal) is a pharmaceutical company that develops, manufactures, and distributes medicines. The company offers generic and specialty pharmaceutical products. Amneal offers products in various dosage forms comprising liquids, sterile injectables, oral solids, powders, nasal sprays, inhalation and respiratory products, transdermal patches, ophthalmics, films, and topicals. It sells its products to wholesalers, chain pharmacies, distributors, hospitals, and individual pharmacies. The company operates in the United States, India, and Ireland. It also operates in distribution centers situated in Pennsylvania, Fountain Run, Kentucky, and Philadelphia. The company has partnered with Baclofen Franchise, Puniska Healthcare Pvt. Ltd., Kashiv Specialty Pharmaceuticals, LLC, AvKARE, LLC, R&S Northeast LLC, and others. Amneal is headquartered in Bridgewater, New Jersey, the US. In October 2022, Amneal Pharmaceuticals, Inc. announced the commercial launch of ALYMSYS® (bevacizumab-maly), a biosimilar referencing Avastin®. ALYMSYS® is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.

Key Companies in the Biosimilar Bevacizumab market include

• Amgen


• AryoGen


• Pharmed


• Biothera


• Boehringer Ingelheim


• Centus Biotherapeutics


• Henlius Biotech


• Innovent Biologics


• Mylan


• mAbxience


• Outlook Therapeutics


• Pfizer


• Prestige Biopharma


• Roche


• Samsung Bio


• TOT Biopharm

Biosimilar Bevacizumab Industry Developments

December 2023: The FDA has approved the fifth bevacizumab biosimilar, Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn), for the treatment of several types of cancer. Avzivi is a humanized monoclonal antibody that inhibits vascular endothelial growth factor and references Genentech’s Avastin (bevacizumab). The biosimilar is also the second product developed by Bio-Thera Solutions, a Guangzhou, China-based pharmaceutical company, to receive FDA approval.

July 2022: Prestige Biopharma Limited and Intas Pharmaceuticals Limited announced that they have entered into a binding agreement for the exclusive partnership and supply of the commercialization of Prestige Biopharma’s bevacizumab biosimilar in various countries.

Biosimilar Bevacizumab Market Segmentation

Biosimilar Bevacizumab Product Outlook

• Avastin


• Mvasi


• Zirabev


• Aybintio


• Other Clinical Trial Products

Biosimilar Bevacizumab Application Outlook

• Colorectal cancer


• Non-small cell lung cancer


• Glioblastoma


• Renal cell carcinoma


• Cervical cancer


• Ovarian cancer

Biosimilar Bevacizumab Distribution Channels Outlook

• Hospital Pharmacy


• Online Pharmacy


• Retail Pharmacy


• Other Direct Distribution Channels

Biosimilar Bevacizumab Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America